Primary Site >> Biliary tract Cancer
Gene >> TACC3
| 1. | |||||||||||
| Journal: | PLoS Genet. 2014 Feb 13;10(2):e1004135. | ||||||||||
| Title: | Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. | ||||||||||
| Author: | Borad, Mitesh J|Champion, Mia D|Egan, Jan B|Liang, Winnie S|Fonseca, Rafael|Bryce, Alan H|McCullough, Ann E|Barrett, Michael T|Hunt, Katherine|Patel, Maitray D|Young, Scott W|Collins, Joseph M|Silva, Alvin C|Condjella, Rachel M|Block, Matthew|McWilliams, | ||||||||||
| PMID: | 24550739 | ||||||||||
| 2. | |||||||||||
| Journal: | Oncologist. 2014 Mar;19(3):235-42. | ||||||||||
| Title: | New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. | ||||||||||
| Author: | Ross, Jeffrey S|Wang, Kai|Gay, Laurie|Al-Rohil, Rami|Rand, Janne V|Jones, David M|Lee, Hwa J|Sheehan, Christine E|Otto, Geoff A|Palmer, Gary|Yelensky, Roman|Lipson, Doron|Morosini, Deborah|Hawryluk, Matthew|Catenacci, Daniel V T|Miller, Vincent A|Churi, C | ||||||||||
| PMID: | 24563076 | ||||||||||
| 3. | |||||||||||
| Journal: | J Hematol Oncol. 2015 May 29;8:58. | ||||||||||
| Title: | HER2/neu-directed therapy for biliary tract cancer. | ||||||||||
| Author: | Javle, Milind|Churi, Chaitanya|Kang, HyunSeon C|Shroff, Rachna|Janku, Filip|Surapaneni, Rakesh|Zuo, Mingxin|Barrera, Christian|Alshamsi, Humaid|Krishnan, Sunil|Mishra, Lopa|Wolff, Robert A|Kaseb, Ahmed O|Thomas, Melanie B|Siegel, Abby B | ||||||||||
| PMID: | 26022204 | ||||||||||
| 4. | |||||||||||
| Journal: | Mol Cancer Res. 2016 May;14(5):458-69. | ||||||||||
| Title: | Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation. | ||||||||||
| Author: | Nelson, Katelyn N|Meyer, April N|Siari, Asma|Campos, Alexandre R|Motamedchaboki, Khatereh|Donoghue, Daniel J | ||||||||||
| PMID: | 26869289 | ||||||||||
| 5. | |||||||||||
| Journal: | Hepatology. 2018 Aug 1. | ||||||||||
| Title: | HSP90 inhibition drives degradation of FGFR2 fusion proteins: implications for treatment of cholangiocarcinoma. | ||||||||||
| Author: | Lamberti, Dante|Cristinziano, Giulia|Porru, Manuela|Leonetti, Carlo|Egan, Jan B|Shi, Chang-Xin|Buglioni, Simonetta|Amoreo, Carla A|Castellani, Loriana|Borad, Mitesh J|Alema, Stefano|Anastasi, Sergio|Segatto, Oreste | ||||||||||
| PMID: | 30067876 | ||||||||||